Advertisement

Molecular Response Prediction in Multimodality Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction

  • Georg LurjeEmail author
  • Heinz-Josef Lenz
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 182)

Abstract

Cancers arising from the esophagus are becoming more common in the United States and Europe. In 2009, an estimate of 14,530 new cases will be diagnosed and more than 90% will die of their disease. Esophageal cancer is currently the most rapidly increasing cancer in the western world and is coinciding with a shift in histological type and primary tumor location. Despite recent improvements in the detection, surgical resection, and (radio-) chemotherapy, the overall survival (OS) of esophageal cancer remains relatively poor. It is becoming increasingly apparent that neoadjuvant chemoradiation followed by surgery may be beneficial in terms of increasing resectability and OS compared to surgery alone. Results from clinical trials are encouraging; however, they also demonstrated that only patients with major histopathological response (pCR) will benefit from neoadjuvant therapy. In addition, these therapies are expensive and the prognoses of patients who do not respond to trimodality treatment strategies appear to be inferior to that of patients who had surgery alone. Accordingly, the development of validated predictive molecular markers may not only be helpful in identifying EA patients who are more likely to respond, but they will also be critical in selecting more efficient treatment strategies with the means of a tailored, targeted, and effective therapy to the molecular profile of both the patient and their disease while minimizing and avoiding life-threatening toxicities.

Keywords

Overall Survival Esophageal Cancer Esophageal Carcinoma Esophageal Adenocarcinoma Survivin mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Supported by Yvonne Bogdanovich and the San Pedro Guild Research Fund.

References

  1. Akamatsu M, Matsumoto T, Oka K et al (2003) c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57:1323–1327PubMedCrossRefGoogle Scholar
  2. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRefGoogle Scholar
  3. Bennett WP, Hollstein MC, Metcalf RA et al (1992) p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 52:6092–6097PubMedGoogle Scholar
  4. Blank KR, Rudoltz MS, Kao GD, Muschel RJ, McKenna WG (1997) The molecular regulation of apoptosis and implications for radiation oncology. Int J Radiat Biol 71:455–466PubMedCrossRefGoogle Scholar
  5. Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26:2–8PubMedGoogle Scholar
  6. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92:549–555PubMedCrossRefGoogle Scholar
  7. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRefGoogle Scholar
  8. Brock MV, Gou M, Akiyama Y et al (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9:2912–2919PubMedGoogle Scholar
  9. Brucher BL, Stein HJ, Zimmermann F et al (2004) Responders benefit from neoadjuvant radio­chemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 30:963–971PubMedGoogle Scholar
  10. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRefGoogle Scholar
  11. Dandekar DS, Lokeshwar BL (2004) Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10:8037–8047PubMedCrossRefGoogle Scholar
  12. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053PubMedCrossRefGoogle Scholar
  13. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252PubMedCrossRefGoogle Scholar
  14. Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637–4642PubMedGoogle Scholar
  15. Fiegl H, Millinger S, Mueller-Holzner E et al (2005) Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65:1141–1145PubMedCrossRefGoogle Scholar
  16. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234PubMedCrossRefGoogle Scholar
  17. Gibault L, Metges JP, Conan-Charlet V et al (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93:107–115PubMedCrossRefGoogle Scholar
  18. Gibson MK, Abraham SC, Wu TT et al (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9:6461–6468PubMedGoogle Scholar
  19. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR (2001) Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 234:520–530; discussion 30–31Google Scholar
  20. Hamilton JP, Sato F, Greenwald BD et al (2006) Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 4:701–708PubMedCrossRefGoogle Scholar
  21. Hamoui N, Peters JH, Schneider S et al (2004) Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg 139:712–716; discussion 6–7Google Scholar
  22. Han B, Liu J, Ma MJ, Zhao L (2005) Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J Gastroenterol 11:2188–2192PubMedGoogle Scholar
  23. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593–1611PubMedCrossRefGoogle Scholar
  24. Herskowitz I (1987) Functional inactivation of genes by dominant negative mutations. Nature 329:219–222PubMedCrossRefGoogle Scholar
  25. Hickey K, Grehan D, Reid IM, O’Briain S, Walsh TN, Hennessy TP (1994) Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 74:1693–1698PubMedCrossRefGoogle Scholar
  26. Hironaka S, Hasebe T, Kamijo T et al (2002) Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8:124–130PubMedGoogle Scholar
  27. Hoffmann AC, Warnecke-Eberz U, Luebke T et al (2007) Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 95:51–54PubMedCrossRefGoogle Scholar
  28. Holscher AH, Schneider PM, Gutschow C, Schroder W (2007) Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 245:241–246PubMedCrossRefGoogle Scholar
  29. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y (1999) Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 86:1396–1405PubMedCrossRefGoogle Scholar
  30. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N (2000) Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann Thorac Surg 70:913–917PubMedCrossRefGoogle Scholar
  31. Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C (2002) Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 21:657–663PubMedCrossRefGoogle Scholar
  32. Inada S, Koto T, Futami K, Arima S, Iwashita A (1999) Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 29:493–503PubMedCrossRefGoogle Scholar
  33. Ishibashi Y, Matsumoto T, Niwa M et al (2004) CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101:1994–2000PubMedCrossRefGoogle Scholar
  34. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988–993PubMedCrossRefGoogle Scholar
  35. Itami A, Shimada Y, Watanabe G, Imamura M (1999) Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 57:311–317PubMedCrossRefGoogle Scholar
  36. Jass JR (2005) Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2:398–405PubMedCrossRefGoogle Scholar
  37. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96PubMedCrossRefGoogle Scholar
  38. Jen J, Wu L, Sidransky D (2000) An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci 906:8–12PubMedCrossRefGoogle Scholar
  39. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRefGoogle Scholar
  40. Joshi MB, Shirota Y, Danenberg KD et al (2005) High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11:2215–2221PubMedCrossRefGoogle Scholar
  41. Karnes WE Jr, Weller SG, Adjei PN et al (1998) Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114:930–939PubMedCrossRefGoogle Scholar
  42. Kase S, Osaki M, Honjo S et al (2003) Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch 442:129–135PubMedGoogle Scholar
  43. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42–49PubMedCrossRefGoogle Scholar
  44. Kishi K, Petersen S, Petersen C et al (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326–1331PubMedGoogle Scholar
  45. Kitamura K, Saeki H, Kawaguchi H et al (2000) Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastro­enterology 47:419–423PubMedGoogle Scholar
  46. Koyanagi K, Mori T, O’Day SJ, Martinez SR, Wang HJ, Hoon DS (2006) Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 66:6111–6117PubMedCrossRefGoogle Scholar
  47. Kraiss S, Quaiser A, Oren M, Montenarh M (1988) Oligomerization of oncoprotein p53. J Virol 62:4737–4744PubMedGoogle Scholar
  48. Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM (2004) Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 127:1579–1586PubMedCrossRefGoogle Scholar
  49. Kuo KT, Chow KC, Wu YC et al (2003) Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 76:909–914PubMedCrossRefGoogle Scholar
  50. Kuwahara M, Hirai T, Yoshida K et al (1999) p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus 12:116–119PubMedCrossRefGoogle Scholar
  51. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–266PubMedCrossRefGoogle Scholar
  52. Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14(spec no 1):R65–R76Google Scholar
  53. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15–16PubMedCrossRefGoogle Scholar
  54. Lecomte T, Berger A, Zinzindohoue F et al (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548PubMedCrossRefGoogle Scholar
  55. Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921PubMedCrossRefGoogle Scholar
  56. Leung WK, To KF, Chu ES et al (2005) Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 92:2190–2194PubMedCrossRefGoogle Scholar
  57. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935PubMedCrossRefGoogle Scholar
  58. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286–2291PubMedGoogle Scholar
  59. Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805PubMedCrossRefGoogle Scholar
  60. Lowe SW, Bodis S, McClatchey A et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807–810PubMedCrossRefGoogle Scholar
  61. Lurje G, Vallbohmer D, Collet PH et al (2007) COX-2 mRNA expression is significan­tly increased in acid-exposed compared to no­nexposed squamous epithelium in gastroeso­phageal reflux disease. J Gastrointest Surg 11:1105–1111PubMedCrossRefGoogle Scholar
  62. Lurje G, Nagashima F, Zhang W et al (2008) Polymorphisms in COX-2 and EGFR are associated with progression-free survival independent of K-ras in mCRC patients treated with single agent cetuximab. Clin Cancer Res 14:7884–7895PubMedCrossRefGoogle Scholar
  63. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, Winder T, Ning Y, Yang D, Klipfel NE, Chandrasoma P, Hagen JA, Demeester SR, Demeester TR, Lenz HJ (2010) Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 251(5):857–864PubMedCrossRefGoogle Scholar
  64. Luthra R, Wu TT, Luthra MG et al (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24:259–267PubMedCrossRefGoogle Scholar
  65. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545–553PubMedCrossRefGoogle Scholar
  66. McLeod HL, Yu J (2003) Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest 21:630–640PubMedCrossRefGoogle Scholar
  67. Metzger R, Leichman CG, Danenberg KD et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309–316PubMedGoogle Scholar
  68. Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH (2004) Molecular biology of esophageal cancer. Onkologie 27:200–206PubMedCrossRefGoogle Scholar
  69. Miyazono F, Metzger R, Warnecke-Eberz U et al (2004) Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 91:666–672PubMedGoogle Scholar
  70. Montesano R, Hollstein M, Hainaut P (1996) Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69:225–235PubMedCrossRefGoogle Scholar
  71. Nakashima S, Natsugoe S, Matsumoto M et al (2000) Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res 20:1933–1937PubMedGoogle Scholar
  72. Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRefGoogle Scholar
  73. Paulson TG, Reid BJ (2004) Focus on Barrett’s esophagus and esophageal adenocarcinoma. Cancer Cell 6:11–16PubMedCrossRefGoogle Scholar
  74. Peyre CG, Demeester SR, Rizzetto C et al (2007) Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg 246:665–674PubMedCrossRefGoogle Scholar
  75. Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRefGoogle Scholar
  76. Reardon JT, Sancar A (2006) Repair of DNA-polypeptide crosslinks by human excision nuclease. Proc Natl Acad Sci U S A 103:4056–4061PubMedCrossRefGoogle Scholar
  77. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV et al (1998) p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7–18PubMedCrossRefGoogle Scholar
  78. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232PubMedCrossRefGoogle Scholar
  79. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal ­cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208PubMedCrossRefGoogle Scholar
  80. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE (1998) Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4:2991–2997PubMedGoogle Scholar
  81. Schneider PM, Baldus SE, Metzger R et al (2005a) Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242:684–692PubMedCrossRefGoogle Scholar
  82. Schneider S, Uchida K, Brabender J et al (2005b) Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 200:336–344PubMedCrossRefGoogle Scholar
  83. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R (2004) Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 67:300–309PubMedCrossRefGoogle Scholar
  84. Sherman CA, Turrisi AT, Wallace MB, Reed CE (2002) Locally advanced esophageal cancer. Curr Treat Options Oncol 3:475–485PubMedCrossRefGoogle Scholar
  85. Shimada Y, Watanabe G, Yamasaki S et al (2000) Histological response of cisplatin predicts patients’ survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 36:987–993PubMedCrossRefGoogle Scholar
  86. Shimada H, Hoshino T, Okazumi S et al (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 86:552–557PubMedCrossRefGoogle Scholar
  87. Shirota Y, Stoehlmacher J, Brabender J et al (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMedGoogle Scholar
  88. Sohda M, Ishikawa H, Masuda N et al (2004) Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 110:838–844PubMedCrossRefGoogle Scholar
  89. Stoehlmacher J, Lenz HJ (2003) Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 30:10–16PubMedGoogle Scholar
  90. Tanioka Y, Yoshida T, Yagawa T et al (2003) Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 89:2116–2121PubMedCrossRefGoogle Scholar
  91. Terashita Y, Ishiguro H, Haruki N et al (2004) Excision repair cross complementing 3 ­expression is involved in patient prognosis and tumor progression in esophageal cancer. Oncol Rep 12:827–831PubMedGoogle Scholar
  92. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493–501PubMedCrossRefGoogle Scholar
  93. Tsujii M, Kawano S, DuBois RN (1997) Cyclo­oxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336–3340PubMedCrossRefGoogle Scholar
  94. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  95. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Rand­omized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313PubMedGoogle Scholar
  96. Usadel H, Brabender J, Danenberg KD et al (2002) Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62:371–375PubMedGoogle Scholar
  97. Vallbohmer D, Peters JH, Oh D et al (2005) Survivin, a potential biomarker in the development of Barrett’s adenocarcinoma. Surgery 138:701–706; discussion 6–7Google Scholar
  98. Vallbohmer D, Kuhn E, Warnecke-Eberz U et al (2008) Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharm­acogenomics 9:681–690PubMedCrossRefGoogle Scholar
  99. Wallner M, Herbst A, Behrens A et al (2006) Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 12:7347–7352PubMedCrossRefGoogle Scholar
  100. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462–467PubMedCrossRefGoogle Scholar
  101. Warnecke-Eberz U, Metzger R, Miyazono F et al (2004) High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10:3794–3799PubMedCrossRefGoogle Scholar
  102. Warnecke-Eberz U, Hokita S, Xi H et al (2005) Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 13:1241–1246PubMedGoogle Scholar
  103. Widschwendter A, Muller HM, Fiegl H et al (2004) DNA methylation in serum and tumors of cer­vical cancer patients. Clin Cancer Res 10:565–571PubMedCrossRefGoogle Scholar
  104. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J (1995) Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897–1905PubMedCrossRefGoogle Scholar
  105. Xi H, Baldus SE, Warnecke-Eberz U et al (2005) High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11:8341–8347PubMedCrossRefGoogle Scholar
  106. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948PubMedCrossRefGoogle Scholar
  107. Zacherl J, Sendler A, Stein HJ et al (2003) Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg 27:1067–1074PubMedGoogle Scholar
  108. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198–204PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of Visceral- and Transplantation SurgeryUniversity Hospital of ZurichZurichSwitzerland

Personalised recommendations